Fractional IR
for Biotech.
Built for the capital markets, scaled to your stage.
Senior, hands-on Investor Relations and strategic communications for European and US-listed life sciences companies — without the overhead of a full-time hire.
In biotech, the choice shouldn’t be between big-agency gloss and a stretched CEO or CFO.
| Big-Firm Retainer | Full-Time Hire | Fractional IR | |
|---|---|---|---|
| Seniority | Junior staff handle day-to-day | One senior hire | Senior leader on every engagement |
| Embedded | External agency | Yes (with full overhead) | Yes, part of your team |
| Commitment | Project- or hour-based | Salary + benefits + equity | Defined share of the week |
| What you get | Polished but generic | Costly, slow to hire | Senior expertise, on-demand |
An IR expert who understands your science and the investor landscape.
What an embedded IR partner delivers, across four areas — from equity story to active investor engagement.
The ‘Bridge & Build’ Model
Pan-European & US Market Reach
We bridge the Atlantic investor gap — fluent in both European and US investor cultures, networks, and expectations.
Science Meets Finance
Deep biotech and pharma sector experience combined with financial services expertise. We speak both languages.
Hands-On Execution
From strategy to implementation — we don't just advise, we do the work, reducing stress on your C-suite.
Credible Equity Story
We build investor trust from the ground up with consistent, compelling narratives that resonate globally.
“I don’t hand off deliverables and disappear. I sit at your table.”
— Alexandra Deschner, Viribus Valorem
Senior IR expertise. Delivered flexibly. Without the overhead.
Immediate Impact
Hit the ground running — no ramp-up, no onboarding burden. Senior-level focus from day one.
Earn Investor Confidence
Secure your next funding round by building the investor trust and engagement your story deserves.
Less Effort for You
Done-for-you IR frees your C-suite to focus on the science, not the investor calendar.
No Long-Term Lock-In
Flexible monthly retainer. Scales up or down as your needs evolve through each milestone.
Low-Risk Start
Begin with a bespoke 30-minute consultation — see the value before you commit.
Words from our clients.
Working with Alexandra felt like having a senior IR lead fully on the team, without the overhead of a permanent hire. Proactive, solution-oriented, and fully aligned with our goals.
Harald
CFO
EURONEXT-LISTED BIOTECHAlexandra hit the ground running and brought immediate stability to our IR function. Her agility and calm under pressure made a real difference.
Jean-Manuel
VP, Head of External Affairs
EURONEXT-LISTED BIOTECHAlexandra reshaped our equity story into something far clearer and more compelling for investors, giving us a much stronger foundation for engaging international VCs and partners.
Romain
Chief Business Officer
LATE-STAGE PRIVATE BIOTECH
Alexandra Deschner
Founder · Fractional IR Partner
25+ years at the intersection of financial markets and life sciences — beginning in financial services in New York and London, then moving in-house and into advisory IR roles across public and private biotech.
Fractional IR partner to small- and mid-cap listed and late-stage private biotech — senior, hands-on support for executive teams that need IR expertise without building a full in-house function.
Works closely with management on equity story, strategic messaging, investor materials, and targeted outreach around financings, clinical milestones, and strategic transitions.
Based in Brussels, with deep experience supporting European-listed biotech — and equally able to help companies engage US capital markets when that’s part of their strategy. Multilingual (English, French, German, Italian).
Ready to build investor trust?
Start with a bespoke 30-minute consultation.
No pressure. No obligation.